Summary Increased understanding of the molecular basis of colorectal cancer and recognition that extracellular DNA circulates in the plasma and serum of cancer patients enables new approaches to detection and monitoring. We used a polymerase chain reaction (PCR) assay to demonstrate mutant K-ras DNA in the plasma or serum of patients with colorectal cancer. Plasma or serum was fractionated from the blood of 31 patients with metastatic or unresected colorectal cancer and from 28 normal volunteers. DNA was extracted using either a sodium chloride or a gelatin precipitation method and then amplified in a two-stage PCR assay using selective restriction enzyme digestion to enrich for mutant K-ras DNA. Mutant K-ras DNA was detected in the plasma or serum of 12 (39%) patients, all confirmed by sequencing, but was not detected in any of the normal volunteers. K-ras mutations were detected in plasma or serum regardless of sex, primary tumour location, principal site of metastasis or proximity of chemotherapy and surgery to blood sampling. Tumour specimens available for 19 of the patients were additionally assayed for ras mutations and compared with blood specimens. Our results indicate mutant K-ras DNA is readily detectable by PCR in the plasma or serum of patients with advanced colorectal cancer. Thus, plasma-or serum-based nucleic acid amplification assays may provide a valuable method of monitoring and potentially detecting colorectal cancer.
Colorectal cancer is a common and often fatal disease for which methods of early detection and monitoring are needed. While early detection and prompt medical intervention can be curative, many patients present with regional or widespread metastasis, reflecting in part the limitations of current screening methods. Mutations of the K-ras oncogene are detected in approximately 40% of patients with colorectal cancer, with these mutations occurring in the later stages of adenoma development and persisting during clonal transformation (Bos et al, 1987; Forrester et al, 1987; Vogelstein et al, 1988) . As most K-ras mutations are restricted to a few adjacent nucleotides of codons 12 and 13, nucleic acid amplification assays, such as the polymerase chain reaction (PCR), can be used to detect small numbers of these mutant ras oncogenes. The diagnostic potential of this tumour-specific approach was demonstrated by Sidransky et al (1992) , who used PCR to detect ras mutations in stool from patients with benign or malignant neoplasms of the colon. PCR has been used to detect K-ras mutations in the sputum of patients with lung cancer (Yakubovskaya et al, 1995) and in both pancreatic secretions and blood from patients with pancreatic cancer (Tada et al, 1993) . Similarly, Hardingham et al (1995) demonstrated that circulating K-ras mutant colorectal cancer cells can be detected in blood using PCR. Nucleic acid amplification assays have also been used to detect circulating cancer cells in the blood of patients with various other malignancies, including lymphoma (Gribben et al, 1994) (Pichert et al, 1994) , prostate cancer (Moreno et al, 1992; Ghossein et al, 1995) , malignant melanoma (Hoon et al, 1995; Smith et al, 1991) , breast cancer (Datta et al, 1994 ) and hepatocellular cancer (Komeda et al, 1995) .
Most PCR-based studies evaluating the blood of cancer patients have focused on the cellular fraction of blood as they attempt to detect circulating cancer cells. An alternative and perhaps more efficacious method to detect mutant K-ras DNA involves analysis of the plasma or serum fraction of blood. Extracellular DNA normally circulates in the plasma component of blood in small amounts (Foumie et al, 1986) , and significant increases in the amount of circulating DNA are noted in patients with cancer (Leon et al, 1977) , possibly correlating with tumour viability (Stroun et al, 1987 (Stroun et al, , 1989 . Shapiro et al (1983) demonstrated that patients with gastrointestinal cancers have significant elevations of serum DNA compared with patients with benign gastrointestinal diseases. Recently, it has been shown that mutated ras oncogene DNA can be detected in plasma or serum by PCR. Sorenson et al (1994) found mutated K-ras DNA in the plasma of three patients with metastatic pancreatic cancer, with the sequences of mutated genes detected in plasma matching those of the primary tumour. Vasioukhin et al (1994) detected N-ras mutations in the plasma of patients with acute myelogenous leukaemia and myelodysplastic syndrome. Vasyukhin et al (1994) have similarly detected mutant K-ras DNA in the plasma from 6 of 15 patients with colorectal cancer.
In this larger study, we combine efficient DNA extraction methods with a sensitive PCR assay to detect mutant K-ras DNA in plasma and serum. We confirm that mutant K-ras DNA is readily detectable in the blood of patients with colorectal cancer, but not in the blood of normal volunteers. These findings suggest that analysis of blood plasma or serum for mutant oncogene DNA might provide a valuable method of monitoring and potentially diagnosing patients with colorectal cancer.
MATERIALS AND METHODS

Specimens
Five to ten millilitres of peripheral blood were collected from 31 patients with metastatic (30 patients) or unresected primary (one patient) colorectal cancer and from 28 normal volunteers. For plasma preparation, EDTA-coated or citrate Vacutainer tubes were used to avoid the potential inhibitory effects of heparin on the amplification assay (Beutler et al, 1990 In extraction method two (six patients, 15 normal volunteers), plasma or serum DNA was co-precipitated with gelatin by a method modified from that of Fournie et al (1986) . A stock 5% (w/v) gelatin solution was prepared by mixing 1 g of gelatin (G8-500, Fisher, Pittsburgh, PA, USA) with 20 pl of sterile, doubledistilled water, autoclaving for 30 min and filtering through a 0.2-gm filter. The resultant solution was sequentially frozen in a dry ice/ethanol bath and thawed at room temperature for a total of five cycles. A working 0.3% gelatin solution was prepared by heating the stock solution to 60°C and mixing 600 p1 of 5% gelatin with 25 pl of 1 M Tris-HCl (pH 8.0) and 9.4 pl of sterile, double-distilled water. One hundred and sixty microlitres of plasma or serum was mixed with 12.8 pl of 0.5 M EDTA and 467 pl of sterile, doubledistilled water, then emulsified for 3 min with 320,l of phenol. The solution was centrifuged at 14 000 g for 10 min, and 570 pl of the aqueous layer was removed to a clean tube. DNA was precipitated by addition of 142 p1 of the 0.3% (w/v) gelatin working solution and 500 pl of cold absolute ethanol, followed by incubation at -20°C for a minimum of 2 h. The samples were microfuged at 4°C for 15 min, washed once with cold 70% ethanol and dried in a 60°C heat block for 10 min. DNA was resuspended by the addition of 70 p1 of sterile, double-distilled water preheated to 60°C. One-half of each sample was used in the PCR assay.
PCR assay
Mutant K-ras oncogene DNA was isolated using a non-radioactive PCR assay adapted from Kahn et al (1991) . PCR was performed as follows: a reaction mixture containing 35 pl of the DNA solution extracted from plasma or serum, 50 mm potassium chloride, 10 mM Tris pH 9.0, 0.1% Triton X-100, 1.5 mm magnesium chloride, 200,M of each dATP, dGTP, dCTP and dTTP, 0.5 pmol oligonucleotide K-ras-L (5'-ACTGAATATAAACTTGTGGTA-GTTGGACCT-3'), 0.75 pmol oligonucleotide K-ras-R (5'-TCAAAGAATGGTCCTGGACC-3') and 1 unit of Taq DNA polymerase (Promega, Madison, WI, USA) in a volume of 50 pl was prepared. The stated ratio of primers was found empirically to provide the cleanest results (not shown). The oligonucleotide K-ras-L is immediately upstream of codon 12 and is modified at the 28th base (G > C) to create an artificial restriction enzyme site (BstNI). The oligonucleotide K-ras-R is modified at the 17th nucleotide (C > G) to create an artificial BstNI site to serve as an internal control for completion of digestion. This approach differs from the original (Kahn et al, 1991) , in which an unmodified K-ras-R primer was used in the first round and the modified primer only in the second round of amplification. Our approach is simpler and yields equivalent sensitivity (data not shown).
The reaction mixture was overlaid with mineral oil and cycled 15 or 20 times at 94°C for 48 s, 56°C for 90 s and 72°C for 155 s in a PHC-2 thermocycler (Techne, Princeton, NJ, USA). Ten microlitres of the PCR mixture were then removed to a new tube, adjusted to be equivalent to 1 x BstNI reaction buffer, and 10 units of BstNI restriction enzyme (Stratagene, La Jolla, CA, USA) were added and then incubated at 60°C for 90 min. A second aliquot of 10 units of BstNI was added and the reaction was continued for 90 min more. Ten microlitres of the digested PCR mixture was then removed to a new tube and a new reaction mixture was set up for the second amplification stage using identical constituents as in the first amplification, except that 7.7 pmol of oligonucleotide K-ras-L and 11.5 pmol of oligonucleotide K-ras-R were used. The same cycling conditions were used for 33 or 35 cycles. A second BstNI restriction digestion was performed using 25 gl of the second-step PCR product and 17 units of enzyme in a final volume of 35 pl. Digestions were performed for 60 min, and then a second aliquot of 10 units of enzyme was added and digested for an additional 60 min. The final digestion product was electrophoresed through a 3% agarose gel.
All amplification assays included a mutated K-ras-positive control consisting of the coron carcinoma cell line GEO (codon 12 K-ras mutation GGT > GCT), a wild-type K-ras (mutant negative) control consisting of DNA from normal placenta tissue and a negative control lacking DNA. In addition, reactions were run in parallel without BstNI digestion to ensure amplification had occurred. Routine precautions to prevent contamination were used in all amplification-based work (Kwok and Higuchi, 1989) . The risk of contamination yielding falsely positive results was further minimized by repeating PCR assays on all patient plasma or serum samples two or three times on different days.
Paraffin tissue extraction DNA was harvested from tissue in available paraffin blocks by cutting 2-4 paraffin sections at a thickness of 15 microns using ethanol-cleaned microtome blades. The tissue was transferred to microfuge tubes and extracted twice with 300 p1 of xylene to British Journal of Cancer (1997) 76(10) PCR assays for K-ras mutations were performed essentially as described, with 35 pul of DNA solution added to the PCR reaction mixture. The two-stage PCR assay consisted of an initial 15-cycle amplification, followed by reamplification of digested products for an additional 30 cycles, with the final product being electrophoresed through a 3% agarose gel. Positive controls (GEO cell line) and negative controls (placenta tissue and reagents without template DNA) were included in all amplification assays. In addition, equivalent amounts of tumour DNA were run in parallel without BstNI digestion to ensure that amplification at the locus had occurred.
Gel electrophoresis
Twenty-five microlitres of the final digestion product were electrophoresed through a 3% agarose (2:1 NuSieve GTG, FMC Bioproducts, Rockland, ME, USA; Molecular Biology Grade Agarose, Promega) gel in 1 x TBE at 75 V DC for approximately 2 h before staining with ethidium bromide. Photographs of the gels were taken on an ultraviolet light transilluminator (Foto-prep, Fotodyne, Hartland, WI, USA). Mutant K-ras DNA was evident on the gel as a single band of length 142 bp, failure of digestion was evident as a band at 157 bp and cleaved non-mutated (wildtype) K-ras DNA was sometimes evident as a band at 113 bp.
Sequence analysis
To confirm results of the plasma and serum specimen assays mutant DNA bands were excised from the agarose gel, reamplified, cloned into the pGEM-T vector plasmid (Promega) and sequenced using a commercial kit (Sequenase 2.0, USB, Cleveland, OH, USA). A minimum of two clones were sequenced for each PCR product, and all gave consistent results.
Clinical correlations
Clinical variables that might affect plasma or serum K-ras detection were reviewed retrospectively. Comparisons were made between detection of mutant K-ras DNA in plasma or serum and patient sex, primary tumour location (colon vs rectum), principal metastatic site (liver vs lung) and proximity of chemotherapy or surgical resection to specimen blood draw. Statistical analysis was performed using Fisher's exact test for a two by two table (two-tail). 
Plasma and serum specimens
All 28 plasma and serum specimens from normal volunteers tested negative for mutant K-ras DNA regardless of extraction method used. Of 31 cancer patient plasma and serum specimens, 12 (39%) were positive for mutant K-ras DNA, with a distinct band seen on the gels at the 142 bp length (Figure 1 ). Positive samples included 8 of the 22 plasma specimens and four of the nine serum specimens. Both extraction methods appeared efficacious, with mutant K-ras detected in 8 of 25 specimens for which extraction method one was used and in four of six specimens for which extraction method two was used. All positive specimens were repeatedly positive on retesting of the specimen. The remaining 19 patient plasma and serum specimens repeatedly tested negative. To make certain that negative results were not due to failed amplifications, specimens were further tested by omitting the initial BstNI digestion. The expected wild-type K-ras band was formed in all cases indicating that amplifiable DNA was present in each sample. In all PCR runs, the positive GEO control tested positive, and the negative placenta and DNA absent controls tested negative. The one patient without evidence of metastatic disease whose blood was drawn before surgical resection of his rectal primary tested negative for mutant K-ras DNA in his blood. His tumour was unavailable for testing.
Tumour specimens
Tissue blocks were available for 19 patients, including 18 patients for whom the primary tumour specimen was available. One patient had only a metastatic nodal specimen available. Additional lymph node blocks were available in three other patients to compare with primary tumour specimens. K-ras mutations were detectable in the tumours or nodes of six (32%) of these patients. Tumours from the remaining 13 patients British Journal of Cancer (1997) 76(10), [1293] [1294] [1295] [1296] [1297] [1298] [1299] 0 Cancer Research Campaign 1997 were negative for mutant K-ras. Plasma and serum specimens were correlated with the available tissue. Of the 19 patients, plasma or serum was positive for mutant K-ras DNA in eight patients, with tumours or nodes being mutant ras positive in five of these patients. Of the 13 patients with primary tumours negative for mutant K-ras DNA, plasma or serum was negative for ras mutations in ten. Thus, K-ras mutations were detectable in the blood but not in the tumours
Sequence analysis
Sequence analysis of plasma and serum PCR products from the 12 mutant ras-positive blood specimens confirmed that the detected K-ras DNA was mutated ( Figure 2 and Table 1 ). These mutations included nine instances of GGT > GAT, two cases of GGT > GCT and one case of GGT > GTT plus GAT. Of note, three patients had mutant ras detected in their blood but not in their tumour. Two of these patients had GGT > GAT mutations, making contamination by the GEO control cell line, which carries a GCT mutation, unlikely. The third patient had a GGT > GCT mutation.
Clinical correlations
All patients (18 men, 13 women) had either metastatic colorectal carcinoma (30 patients) or an unresected but not metastatic primary rectal cancer (one patient) at the time of their blood draw, with parenchymal metastasis involving predominantly liver (18 patients), lung (five patients), both liver and lung (five patients) or omentum/ascites (two patients). Initial primary tumours originated from the colon in 20 patients and from the rectum in 11 patients. Mutant K-ras DNA could be detected in patient plasma or serum regardless of patient sex, initial primary tumour location (colon vs rectum) or principal parenchymal metastatic site (liver vs lung). Differences in the detection of mutant ras DNA among patients grouped by these clinical variables were not significant, although group sizes were small ( Table 2 ). The proximity of specimen blood draw to chemotherapy and surgery were further investigated. While recognizing that advanced colorectal cancer responds poorly to chemotherapy, it is possible that chemotherapy might increase circulating mutant ras through cellular necrosis or apoptosis or might decrease circulating mutant ras by a reduction in tumour burden. Chemotherapeutic histories were available for 29 patients. Of these, 13 patients had a history of having received chemotherapy within 3 months before their specimen blood draw, with mutant K-ras DNA detected in the plasma or serum of five of these patients, including three of the seven patients who had received chemotherapy within the preceding month. However, 13 other patients had their blood sample drawn before initiation of chemotherapy, i.e. while still chemotherapy-naive (nine patients), or after having been chemotherapy-free for at least 6 months (four patients). Mutant K-ras DNA was detected in the plasma or serum in six of these patients (four chemotherapy-naive patients, two chemotherapyfree patients). Differences regarding circulating mutant ras DNA in the recent chemotherapy and chemotherapy-naive/-free groups were not significant (P = 1.00). Similarly, surgery might release circulating tumour cells or traumatize cells, promoting mutant ras detection. However, of the 12 patients with K-ras mutations detected in their blood, only one patient had the blood specimen drawn within 1 month after surgery, while seven had their blood specimen drawn more than 1 year after surgery. Conclusions cannot be extrapolated to the intraoperative and immediate postoperative periods, as no blood specimens were obtained during these times. Thus, the above data demonstrate that mutant K-ras DNA circulates in plasma or serum even without recent surgical trauma or chemotherapy-induced necrosis or apoptosis. Blood specimens from 16 patients were collected in 1988 and stored frozen. Mutations were detected in the plasma or serum in four of these specimens, indicating that mutant K-ras DNA can be detected in plasma and serum frozen long term. Whether the sensitivity of the assay is diminished when specimens are stored under these conditions remains uncertain.
DISCUSSION
Mutation of the K-ras oncogene is recognized as an early and frequent mutational event in the pathogenesis of colorectal cancer, making it a potentially valuable clinical marker. As the location of ras point mutations is fairly restricted, with most occurring at codons 12, 13 or 61, they are particularly amenable to detection by nucleic acid amplification assays (Bos, 1989) . In this study we have combined DNA extraction methods with a non-radioactive PCR assay to demonstrate that mutant K-ras DNA is readily detectable in the plasma and serum of patients with advanced colorectal cancer. The presence of mutant ras DNA in plasma has similarly been demonstrated by others. Sorenson et al (1994) combined a dialysis-based DNA extraction procedure with PCR to detect mutant K-ras DNA in the plasma of patients with pancreatic cancer. Vasioukhin and associates (1994) used PCR to amplify DNA extracted from plasma through centrifugation on a caesium sulphate gradient and were able to demonstrate circulating N-ras mutations in patients with leukaemia and myelodysplastic syndrome. Vasyukhin et al (1994) similarly extracted DNA from the plasma of patients with colorectal cancer and were able to amplify mutant K-ras DNA. While we used different DNA extraction methods, sensitivity and reproducibility were maintained. DNA extraction method two in particular has the advantage of being rapid, with DNA extracted from plasma in as little as 3 h.
Although we did not demonstrate complete concordance between K-ras mutations in plasma or serum and those in tumours, it appears that we were able to detect most cases with circulating mutant K-ras DNA. Our detection of circulating mutant ras in 39% of the patients is similar to what would be expected based upon the incidence of K-ras mutations in colorectal cancer. There was a single case of a primary tumour bearing a K-ras mutation that was not detectable in blood. Of interest, examination of a metastatic node from the patient also failed to detect mutant ras, raising the possibility that the patient's remaining metastatic tumours either lost or never carried the mutation. Three patients had K-ras mutations detectable in their blood but not in their primary tumours. Results for these three patients probably indicate circulating extracellular mutant K-ras DNA, with several factors making contamination unlikely: all normal control specimens tested negative; placenta and DNA-absent controls tested negative; results were consistently reproducible upon retesting of the specimens; and sequence analysis confirmed specific mutations, of which two of the three cases differed from the positive control. Other investigators have reported ras mutations in the metastasis but not in the corresponding primary tumour, or in the primary tumour but not in the metastasis (Oudejans et al, 1991) . Sampling of blood plasma or serum might prove a particularly efficacious means of detecting mutant DNA should such tumour heterogeneity be present, because it effectively screens the entire tumour burden.
It is not known whether mutant K-ras DNA in plasma and serum represents extracellular DNA released from viable tumour, DNA released from necrotic or apoptotic cells or DNA released from the lysis of fragile circulating cancer cells. It is well documented that circulating cancer cells can be detected in blood (Hardingham et al, 1995) . However, it has been observed both by us and by others (Vasioukhin et al, 1994; Vasyukhin et al, 1994 ) that mutant ras can be detected in plasma even when not detected in the cellular fraction of blood, suggesting that circulating cancer cells may not be involved. Cellular necrosis and apoptosis are common processes in cancer. Conceivably, such processes could yield detectable amounts of extracellular DNA, either as free DNA or as membrane-bound apoptotic bodies. An alternative possibility is that detectable extracellular DNA is being shed from viable tumour (Leon et al 1977) . An active release of DNA that appears to be independent of cell death but under regulatory control has been demonstrated in lymphocytes (Rogers et al, 1972; Anker et al, 1975) . Furthermore, DNA has been demonstrated on the cell surface of malignant cell lines (Aggarwal et al, 1975; Juckett and Rosenberg, 1982) . It is commonly assumed that shed extracellular DNA would be susceptible to digestion by plasma DNAases. However, Leon et al (1981) found inhibitors of DNAase in the plasma of cancer patients, which might lead to accumulation of circulating DNA. Others have suggested that DNA is shed in a protein or proteolipid complex and is thus resistant to degradation (Rogers et al, 1974; Stroun et al, 1977 Stroun et al, , 1987 .
Regardless of the origin of this extracellular DNA, the use of plasma-based nucleic acid amplification assays to detect tumourspecific extracellular DNA represents a new and potentially valuable approach to cancer detection and monitoring. This initial study was limited primarily to patients with metastatic disease, and the use of our assay in detecting early disease remains undefined. In general, the applicability of K-ras assays to cancer detection and monitoring will be limited by the incidence of K-ras mutations, with over half of colorectal cancers reported to be mutant Kras negative. However, the concept of selective amplification of mutant DNA from plasma or serum can be extended to other oncogenes and tumour-suppressor genes, including p53, which is frequently mutated in colorectal cancer. Although the mutated nucleotides in the p53 gene are not as clustered as in the K-ras oncogene, a panel or multiplex approach using a number of primers could allow increased detection of cancers. Furthermore, it has recently been demonstrated that tumour-associated microsatellite alterations can be detected in the plasma DNA of small-cell lung cancer patients (Chen et al, 1996) and the serum DNA of head and neck cancer patients (Nawroz et al, 1996) . As microsatellite alterations are often present in colorectal tumours (Lothe et al, 1993; Bocker et al, 1996) , they should similarly be detectable in the plasma and serum DNA of colorectal patients. Plasma and serum-based assays aimed at cancer monitoring might additionally be improved using a quantitative PCR approach. The screening, diagnostic and monitoring potential of detecting oncogenes or other tumour-associated DNA in plasma and serum and the pathophysiological function and clinical implication of their presence warrant further investigation.
